Nanoformulations of Anticancer FGFR Inhibitors with Improved Therapeutic Index

Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Nanomedicine
Egile Nagusiak: Kallus, Sebastian, Englinger, Bernhard, Senkiv, Julia, Laemmerer, Anna, Heffeter, Petra, Berger, Walter, Kowol, Christian R., Keppler, Bernhard K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611408/
https://ncbi.nlm.nih.gov/pubmed/30121385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2018.08.001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak